



Article

Prevalence and Antimicrobial Resistance Diversity of *Salmonella* Isolates in Jiaxing City, China

Ping Li ^{1,†}, Li Zhan ^{2,†}, Henghui Wang ¹, Yong Yan ¹, Miaomiao Jia ¹, Lei Gao ¹, Yangming Sun ¹, Guoying Zhu ^{1,*} and Zhongwen Chen ^{1,*}

¹ Jiaxing Key Laboratory of Pathogenic Microbiology, Jiaxing Center for Disease Control and Prevention, Jiaxing 314050, China; plijxcdc@163.com (P.L.)

² Institute of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou 310051, China; lzhan@cdc.zj.cn

* Correspondence: jxcdczhuguoying@163.com (G.Z.); czw2007@sohu.com (Z.C.)

† These authors contributed equally to this work.

Abstract: Nontyphoidal *Salmonella* (NTS) is a cause of foodborne diarrheal diseases worldwide. Important emerging NTS serotypes that have spread as multidrug-resistant high-risk clones include *S. Typhimurium* monophasic variant and *S. Kentucky*. In this study, we isolated *Salmonella* in 5019 stool samples collected from patients with clinical diarrhea and 484 food samples. Antibiotic susceptibility testing and whole-genome sequencing were performed on positive strains. The detection rates of *Salmonella* among patients with diarrhea and food samples were 4.0% (200/5019) and 3.1% (15/484), respectively. These 215 *Salmonella* isolates comprised five main serotypes, namely *S. Typhimurium* monophasic variant, *S. Typhimurium*, *S. London*, *S. Enteritidis*, and *S. Rissen*, and were mainly resistant to ampicillin, tetracycline, chloramphenicol, and trimethoprim/sulfamethoxazole. The MDR rates of five major serotypes were 77.4%, 56.0%, 66.7%, 53.3%, and 80.0%, respectively. The most commonly acquired extended-spectrum β-lactamase-encoding genes were *bla*_{TEM-1B}, *bla*_{OXA-10}, and *bla*_{CTX-M-65}. The *S. Typhimurium* monophasic variant strains from Jiaxing City belonged to a unique clone with broad antibiotic resistance. *S. Kentucky* isolates showed the highest drug resistance, and all were MDR strains. The discovery of high antibiotic resistance rates in this common foodborne pathogen is a growing concern; therefore, ongoing surveillance is crucial to effectively monitor this pathogen.

Keywords: prevalence; *Salmonella*; monophasic variant; *S. Kentucky*; clinical diarrhea and food samples; AMR; plasmid replicons; WGS



Citation: Li, P.; Zhan, L.; Wang, H.; Yan, Y.; Jia, M.; Gao, L.; Sun, Y.; Zhu, G.; Chen, Z. Prevalence and Antimicrobial Resistance Diversity of *Salmonella* Isolates in Jiaxing City, China. *Antibiotics* **2024**, *13*, 443. <https://doi.org/10.3390/antibiotics13050443>

Academic Editor: Marc Maresca

Received: 12 April 2024

Revised: 11 May 2024

Accepted: 12 May 2024

Published: 14 May 2024



Copyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

1. Introduction

Nontyphoidal *Salmonella* (NTS), which is one of four causes of foodborne diarrheal diseases worldwide, usually causes self-limiting gastrointestinal infections in humans [1,2]. Outbreaks caused by *Salmonella* infection are a complex public health and economic issue worldwide and necessitate urgent action [3,4]. To date, over 2600 serotypes of *Salmonella* have been identified [5], including more than 2000 NTS serotypes, which predominantly comprise *S. Enteritidis*, *S. Typhimurium*, *S. Newport*, and *S. Heidelberg* [6]. Moreover, invasive NTS (iNTS) causes invasive disease and systemic infections such as bacteremia, meningitis, and other focal infections in children, the elderly, and the immunocompromised [7]. The most predominant iNTS serovars are *S. Typhimurium*, *S. Choleraesuis*, and *S. Dublin* [8,9]. Genetic virulence factors associated with the ability of *S. Dublin* to invade humans' blood have been well characterized by whole-genome sequencing [10]. A monophasic variant of *S. Typhimurium* (4,[5],12:i:-), which fails to express the second-phase flagellar antigen FljB, has emerged as a major global cause of NTS disease in animals and humans [11–13].

Antimicrobial resistance (AMR) is a global public health concern. *Salmonella* is one microorganism in which resistant serotypes have emerged because of the widespread use of antibiotics in the production of food animals as well as the indiscriminate use of antibiotics in clinics [14]. Commonly isolated serotypes, including *S. Enteritidis*, *S. Typhimurium*, *S. Newport*, and *S. Typhimurium* monophasic variant, have shown higher rates of AMR compared with minor serotypes of *Salmonella* infections from many countries [15,16]. CTX-M and TEM have been reported as the predominant types of extended-spectrum beta-lactamase (ESBL) enzymes in *Salmonella* [17]. ESBL-producing *Salmonella* isolates confer resistance to some of the antibiotics commonly used in humans, including third-generation cephalosporins [18]. Phage therapy was considered as an alternative to antibiotics for the treatment of antibiotic-resistant bacterial infections. Genomic analysis of Anderson typing phages of *S. Typhimurium* was used to understand the complex dynamics of bacteria–phage interaction through characterizing the genetic determinants that are responsible for their differing host ranges [19].

The *S. Typhimurium* monophasic variant (4,[5],12:i:-) serotype emerged from *S. Typhimurium* (4,[5],12:i:2) and is characterized by its lack of expression of the second-phase flagellar antigen FljB [20]. Since its identification in poultry in the late 1980s [21], isolates of 4,[5],12:i:- have spread rapidly and have been reported in various countries at different times [22,23]. Studies of *S. Typhimurium* monophasic variant strains have found that most are multidrug-resistant [11,24,25]. Tn6029 transposon encodes resistance to ampicillin (*bla*_{TEM-1}), sulfonamides (*sul2*), and streptomycin (*aph(3'')*-*Ib* and *aph(6')-Id*) together with the *tet(B)* gene carried on Tn10, which contributes to the ampicillin, streptomycin, sulfonamide, and tetracycline (ASSuT) resistance profile of *Salmonella* 4,[5],12:i:-. Moreover, the *tet(B)* as well as remaining ASSuT genes could be integrated into the chromosome of *S. Typhimurium* monophasic variant strains. In contrast, the ASSuT profile was plasmid-mediated for *tet(A)*-carrying monophasic *S. Typhimurium* isolates [26]. Furthermore, chromosome- and plasmid-mediated colistin resistance have also been reported in *Salmonella* 4,[5],12:i:- isolates [27].

The high rates of prevalence and AMR have impacted public health. *S. Kentucky* sequence type (ST)198 is mostly isolated from chickens and humans [28,29]. *bla*_{CTX-M-55}, *rmtB*, *tet(A)*, *floR*, and *fosA3*, together with amino acid substitution in *gyrA* (S83F and D83N) and *parC* (S80I), have contributed to the high resistance to ciprofloxacin, cephalosporin, and fluoroquinolones in *S. Kentucky* isolates [30–32]. The IncHI2 plasmid carries numerous resistance genes including *bla*_{CTX-M}, *aadA7*, *lnu(F)*, *bla*_{TEM-1b}, *rmtB*, and *mph(A)*, except for *bla*_{CTX-M-14b}, which is inserted into the chromosomes of *S. Kentucky* isolates, enabling them to transfer vertically as intrinsic chromosomal genes within this lineage. *bla*_{CTX-M-14b} in *S. Kentucky* ST198 also has been reported as chromosomally located [33]. The *S. Kentucky* ST198 could be genetically divided into two clades, namely ST198.1 and ST198.2. Moreover, the clade ST198.2 contains two subclades, namely ST198.2-1 and ST198.2-2, in China. Co-existence of the ESBL-encoding genes *bla*_{CTX-M-55} and *bla*_{TEM-1b} in ST198.2-2 is one of the characteristics of resistance genes different from the *bla*_{CTX-M-14b} in ST198.2-1 [17].

This study aimed to analyze the prevalence, AMR, and genetic characteristics of 215 clinical and foodborne *Salmonella* isolates collected from Jiaxing City in 2023. Our findings provide a basis for the prevention and control of AMR in *Salmonella*.

2. Results

2.1. *Salmonella* Prevalence and Serotypes

A total of 215 *Salmonella* isolates were obtained in 2023 including 200 from clinical samples of patients with diarrhea and 15 from food samples. Of the 35 serotypes identified, the top five were *S. Typhimurium* monophasic variant, *S. Typhimurium*, *S. London*, *S. Enteritidis*, and *S. Rissen*, accounting for 39.1%, 11.6%, 7.0%, 7.0%, and 4.7%, respectively.

The detection rate of *Salmonella* among patients with diarrhea was 4.0% (200/5019). Among the 5019 cases of diarrhea reported, the ratio of males to females was 1.09:1, and the 21- to 30-year-old age group was most common. Children under the age of 10 accounted

for 9.1%. Of the 200 confirmed cases of *Salmonella* infection, 122 were male and 78 were female. The median age of infected patients was 26 years (range: 1 month to 81 years). Predominant symptoms included diarrhea (98.2%), abdominal pain (36.8%), and vomiting (26.5%). Few (9.4%) had fever. *S. Typhimurium* monophasic variant was the predominant serotype in all age groups, mainly in children < 6 years. Serotype diversity was highest in cases aged 6–55 years. A total of 24 serotypes were characterized in this group (Table S1 and Figure 1).




Figure 1. Serotype distribution of *Salmonella* isolates in different groups.

Fifteen *Salmonella* isolates were collected from food samples. The overall percentage of food-positive samples was 3.1% (15/484). Six (6/15) were isolated from raw animal meat, including fresh pork and frozen mutton. Five (5/15) were from freshwater animal products, namely fresh carp, live grass carp, live bass, and *Bellamya quadrata*. Two isolates each were from seasoned raw meat (2/15) and Chinese salad (2/15). The top three serotypes of the foodborne isolates were *S. Thompson*, *S. Corvallis*, and *S. Typhimurium* monophasic variant (Table S1).

2.2. Phenotypic AMR Patterns

Using antibiotic susceptibility tests, we determined that more than half of the isolates were resistant to ampicillin (158/215, 73.5%), tetracycline (149/215, 69.3%), chloramphenicol (124/215, 57.7%), and trimethoprim/sulfamethoxazole (110/215, 51.2%). Only 29 isolates (22.9%) demonstrated susceptibility to all 22 antibiotics tested (Table 1). Over half of the isolates (134/215, 62.3%) were multidrug resistance (MDR). All isolates of *S. Kentucky* and nine other rare serotypes had MDR. All isolates belonged to nine rare serotypes that exhibited MDR, probably because of the small number of them. The percentage of MDR in *S. Rissen*, *S. Typhimurium* monophasic variant, *S. Derby*, *S. London*, *S. Goldcoast*, *S. Agona*, *S. Typhimurium*, *S. Enteritidis*, and *S. Thompson* were 80%, 77.4%, 75.0%, 66.7%, 66.7%, 66.7%, 56.0%, 53.3%, and 50%, respectively (Table 2). *S. Typhimurium* monophasic variant isolates, the core serotype among patients, exhibited high rates of resistance to tetracycline, ampicillin, chloramphenicol, trimethoprim/sulfamethoxazole, and ampicillin/sulbactam (96.4%, 94.1%, 73.8%, 64.3%, and 56.0%, respectively). Over half of *S.*

Typhimurium isolates showed resistance to ampicillin, tetracycline, chloramphenicol, and trimethoprim/sulfamethoxazole. The highest antibiotic resistance rates were observed in the six *S. Kentucky* isolates, all of which were resistant to tetracycline, ampicillin, cefazolin, cefotaxime, ciprofloxacin, and nalidixic acid. Most (5/6) of the *S. Kentucky* isolates were also resistant to chloramphenicol and trimethoprim/sulfamethoxazole (Table 1). The two *S. Kentucky* isolates belonging to subclade ST198.2-2 exhibited additional resistance to azithromycin, gentamicin, and ceftazidime, in contrast to the four subclade ST198.2-1 isolates (Table S2). Rates of resistance to chloramphenicol, tetracycline, ampicillin, and trimethoprim/sulfamethoxazole among the 15 foodborne isolates were 60.0%, 53.3%, 40.0%, and 40.0%, respectively.

Table 1. Antimicrobial resistance for *Salmonella* isolates collected from this study.

Antibiotics	All	<i>S. Typhimurium</i> Monophasic Variant (n = 84)	<i>S. Typhimurium</i> (n = 25)	<i>S. Kentucky</i> (n = 6)	Food Isolates (n = 15)
TET	69.3%	96.4%	60.0%	100.0%	53.3%
AMP	73.5%	94.1%	80.0%	100.0%	40.0%
CHL	57.7%	73.8%	56.0%	83.3%	60.0%
SXT	51.2%	64.3%	48.0%	83.3%	40.0%
AMS	39.1%	56.0%	24.0%	50.0%	13.3%
CFZ	30.2%	38.1%	28.0%	100.0%	6.7%
CTX	21.4%	33.3%	8.0%	100.0%	6.7%
GEN	19.5%	25.0%	4.0%	50.0%	26.7%
CIP	15.4%	13.1%	4.0%	100.0%	6.7%
FEP	8.8%	13.1%	8.0%	33.3%	0.0%
CAZ	7.9%	10.7%	4.0%	33.3%	0.0%
NAL	22.3%	8.3%	28.0%	100.0%	13.3%
AZM	8.8%	4.7%	8.0%	33.3%	13.3%
AMC	1.4%	1.2%	0.0%	0.0%	0.0%
CFX	2.3%	1.2%	0.0%	0.0%	0.0%
CT	4.2%	1.2%	4.0%	0.0%	0.0%
POL	1.9%	1.2%	0.0%	0.0%	0.0%
CZA	0.00%	0.00%	0.0%	0.0%	0.0%
AMI	0.00%	0.00%	0.0%	0.0%	0.0%
IPM	0.00%	0.00%	0.0%	0.0%	0.0%
MEM	0.00%	0.00%	0.0%	0.0%	0.0%
ETP	0.00%	0.00%	0.0%	0.0%	0.0%

Table 2. The percentage of MDR among different serotypes.

Serotypes	MDR	Total	Percentage
<i>S. Kentucky</i>	6	6	100.0%
<i>S. Montevideo</i>	2	2	100.0%
<i>S. Muenster</i>	1	1	100.0%
<i>S. Kedougou</i>	1	1	100.0%
<i>S. Infantis</i>	1	1	100.0%
<i>S. Indiana</i>	1	1	100.0%
<i>S. IIIb 61:i:e,n,x,z15</i>	1	1	100.0%
<i>S. Fanti</i>	1	1	100.0%
<i>S. Anatum</i>	1	1	100.0%
<i>S. Albany</i>	1	1	100.0%
<i>S. Rissen</i>	8	10	80.0%
<i>S. Typhimurium monophasic variant</i>	65	84	77.4%

Table 2. Cont.

Serotypes	MDR	Total	Percentage
S. Derby	3	4	75.0%
S. London	10	15	66.7%
S. Goldcoast	4	6	66.7%
S. Agona	2	3	66.7%
S. Typhimurium	14	25	56.0%
S. Enteritidis	8	15	53.3%
S. Thompson	3	6	50.0%
S. Stanley	1	2	50.0%
S. Corvallis	0	5	0.0%
S. Newport	0	4	0.0%
S. Wil	0	3	0.0%
S. Give	0	3	0.0%
S. Potsdam	0	2	0.0%
S. Lichfield	0	2	0.0%
S. Braenderup	0	2	0.0%
S. Oranienburg	0	1	0.0%
S. Virchow	0	1	0.0%
S. Saintpaul	0	1	0.0%
S. Orion	0	1	0.0%
S. Livingstone	0	1	0.0%
S. Johannesburg	0	1	0.0%
S. Grumpensis	0	1	0.0%
S. Bareilly	0	1	0.0%
Total	134	215	62.3%

2.3. AMR Genes and Plasmid Replicons

Next, AMR genotyping was performed using ResFinder 4.1. As shown in Tables S1 and S3, we identified 71 different AMR genes in the 215 *Salmonella* strains. Apart from ESBL-encoding genes and AmpC β-lactamases, the major forms of AMR were the chloramphenicol resistance gene *floR* in 92 isolates (92/215), the sulfonamide resistance gene *sul2* (91/215), and the quinolone resistance gene *qnrS1* (81/215). The fosfomycin resistance gene *fosA7* was exclusively found in the chromosomes of each isolate of *S. Agona* (3/3), *S. Derby* (4/4), and *S. Grumpensis* (1/1). There were 48 and 29 distinct resistant genes detected in *S. Typhimurium* monophasic variant and *S. Typhimurium* isolates, respectively (Table S3). The most prevalent AMRs in monophasic *S. Typhimurium* were *bla_{TEM-1B}* followed by *tet(B)*, *sul2*, and *qnrS1*. The top three AMRs carried by *S. Typhimurium* were *bla_{TEM-1B}*, *floR*, and *sul2*. However, the proportion of *aph(6')-Id*, *aph(3'')-Ib*, and *tet(B)* in *S. Typhimurium* monophasic variant is much higher than that in *S. Typhimurium*. The tetracycline efflux pump gene *tet(B)* was only found in monophasic *S. Typhimurium* strains. The prevalences of lincosamide resistance gene *lnu(F)*, trimethoprim resistance gene *dfrA14*, ESBL-encoding genes such as *bla_{OXA-10}* and *bla_{CTX-M-65}*, and rifampin resistance gene *arr-2* were much higher in *S. Typhimurium* monophasic variant isolates than in *S. Typhimurium* and other serotype isolates. In contrast, *tet(A)* and *tet(M)* were more prevalent in *S. Typhimurium* compared to its monophasic variant (Tables S1 and S3).

Almost half of (109/215) the *Salmonella* isolates were found to be positive for plasmid replicons' sequence. A total of 32 types of plasmid replicons were detected, with IncQ1 being the most abundant ($n = 50$), followed by IncHI2/IncHI2A ($n = 24$) and IncR ($n = 18$) (Figure 2). Also, some types of plasmids exhibited perfect correspondence to the serotypes; for example, IncQ1 was only detected in *S. Typhimurium* monophasic variant isolates, and IncFIB(S)/IncFII(S)/IncX1 was mainly detected in *S. Enteritidis*. IncHI1A/IncHI1B was only found in *S. Goldcoast* isolates. The most commonly acquired ESBL-encoding genes detected among these strains were *bla_{TEM-1B}* (120/215), followed by *bla_{OXA-10}* (23/215) and *bla_{CTX-M-65}* (21/215). Four *bla_{CTX-M}* subtypes (*bla_{CTX-M-55}*, *bla_{CTX-M-14}*, *bla_{CTX-M-65}*, and *bla_{CTX-M-24}*), three *bla_{OXA}* subtypes (*bla_{OXA-1}*, *bla_{OXA-10}*, and *bla_{OXA-16}*), and two *bla_{TEM}*

subtypes (*bla*_{TEM-1B} and *bla*_{TEM-1A}) were identified among these strains. One *S. Kedougou* isolate and one *S. Typhimurium* monophasic variant were found to be positive for *bla*_{LAP-2}. The *bla*_{DHA-1} and *bla*_{CARB-2} were carried by one *S. Stanley* isolate and one *S. Albany* isolate, respectively. In addition, mobile colistin resistance gene *mcr-1.1* was detected along with *bla*_{TEM-1B} and *bla*_{CTX-M-14} in one *S. Typhimurium* monophasic variant strain (Table S1).




Figure 2. Types of plasmid replicons in *Salmonella* isolates.

2.4. Chromosomal Point Mutation in the Quinolone Resistance-Determining Regions

In total, 106 isolates exhibited corresponding mutations in the *parC* gene and/or *gyrA* gene. Two-point mutations occurred within both the *parC* gene and *gyrA* gene for all *S. Kentucky* isolates, namely Ser (83) to Phe and Ser (83) to Tyr within the *gyrA* gene together with Ser (80) to Ile and Thr (57) to Ser for the *parC* gene. Apart from *S. Kentucky* isolates, there were 76 isolates that exhibited a mutation from Thr (57) to Ser in the *parC* gene. Within *gyrA*, 14 isolates presented one replacement in amino acid 83, with three having a change from Ser (83) to Phe, and the other 11 were from Ser (83) to Tyr. Also, there were 17 isolates that presented one replacement in *gyrA* in amino acid 87 with only one isolate having a change from Asp (87) to Gly and the other 16 being from Asp (87) to Tyr. Mutations occurred only within *gyrA* for all *S. Enteritidis* isolates. Most of them had a p.D87Y mutation, while only two isolates exhibited p.S83Y mutation. Most *S. Typhimurium* monophasic variant isolates had mutations neither in *gyrA* nor in *parC* (Table S1).

2.5. Phylogenetic Analysis

Using whole-genome sequencing (WGS) analysis, 39 distinct STs were identified among the 215 *Salmonella* isolates, with the predominant ST34 accounting for 39.1% (84/215), followed by ST19 at 11.6% (25/215), ST11 at 7.0% (15/215), ST155 at 7.0% (15/215), and ST469 at 4.7% (10/215). Remarkably, some of the STs exhibited perfect correspondence to the serotypes, including ST34 for *S. Typhimurium* monophasic variant and ST155 for *S. London*. There were also pairs of STs that corresponded to the same serotype, including ST654 and ST516 for *S. Give*, ST2529 and ST358 for *S. Goldcoast*, ST2039 and ST408 for *S. Potsdam*, and ST166 and ST46 for *S. Newport*.

To assess genetic variation among these isolates, we conducted phylogenetic analysis of the 203 isolates. As shown in Figure 3, all isolates were classified into two distinct clusters. Cluster A comprised 69 isolates belonging to 24 different STs: ST198, ST292, ST10035, ST1543, ST2060, ST4, ST654, ST23, ST515, ST321, ST516, ST8334, ST13, ST469, ST10422, ST1541, ST40, ST2529, ST358, ST16, ST32, ST64, ST543, and ST11. Cluster B included 134 isolates, representing 14 distinguishable STs: ST684, ST203, ST26, ST22, ST2039, ST408, ST166, ST46, ST214, ST29, ST155, ST49, ST19, and ST34. Cluster B was further subdivided into B-1 and B-2. Cluster B-2 contained all *S. Typhimurium* monophasic

variant and *S. Typhimurium* isolates, as well as one *S. Saintpaul* isolate. Interestingly, 15 of the *S. Typhimurium* isolates shared more similarities with five *S. Typhimurium* monophasic variant isolates than with 10 of the other *S. Typhimurium* strains, suggesting a potential genetic relatedness between these isolates.




Figure 3. Maximum likelihood tree of 203 *Salmonella* isolates in this study. Blue boxes indicate the presence of ESBLs and colistin resistance genes (*bla*_{CTX-M-55}, *bla*_{CTX-M-14b}, *bla*_{CTX-M-14}, *bla*_{CTX-M-65}, *bla*_{CTX-M-24}, *bla*_{TEM-1B}, *bla*_{TEM-1A}, *bla*_{OXA-1}, *bla*_{OXA-10}, *bla*_{OXA-16}, *bla*_{DHA-1}, *bla*_{CARB-2}, *bla*_{LAP-2}, *mcr-1.1*).

3. Discussion

In this study, we determined the prevalence and genetic diversity of *Salmonella* strains isolated from clinical and food samples collected in Jiaxing City, China. The detection rate of *Salmonella* among individuals with diarrhea was 3.98% (200/5019), which was consistent with previous findings obtained in Ethiopia and lower than that in Shanghai [34,35]. Several studies have demonstrated the dominant prevalence of monophasic *S. Typhimurium* in human, food, and environmental samples [36,37]. Similar to previous studies, *S. Typhimurium* monophasic variant 4,[5],12:i:- was the top serotype among our patients with diarrhea, especially among the younger age groups [38]. Among the foodborne isolates, we identified *S. Thompson*, *S. Corvallis*, and *S. Typhimurium* monophasic variant as the three major serotypes, in contrast to *S. Typhimurium* conducted in Huzhou district, Zhejiang province [39].

Salmonellosis outbreaks are linked to the consumption of contaminated food products, including broiler meat, pork, egg, chocolate, and chocolate products [40,41]. The percentage of *Salmonella*-positive samples (10.4%) in freshwater animal products was higher in the present study than in other studies [42]. Marine products including fresh carp, live grass carp, live bass, and Bellamya quadrata have been shown to be contaminated by *Salmonella*, indicating that aquatic products remain an important reservoir of *Salmonella* contamination and possible fecal contamination [43]. NTS outbreaks associated with chocolate consumption have occurred in multiple countries [44,45]. However, this type of food was not positive for NTS in our study.

A variety of ESBL genes, including *bla_{TEM}*, *bla_{CTX-M}*, *bla_{SHV}*, *bla_{ACC}*, and *bla_{CMY}*, could be carried by *Salmonella* isolates [46]. In this study, we had found a wide distribution of the ESBL-encoding gene *bla_{TEM-1B}* in different serotypes of *Salmonella* isolates. The *bla_{CTX-M-55}* type is mediated by MDR IncA/C2 and IncHI2 plasmids in *S. enterica* from pork and fish samples [47]. A recent study also demonstrated the cross-species dissemination of the *bla_{CTX-M-55}*-positive IncHI2 plasmid by chromosome–plasmid conjugation [48]. In this study, *bla_{CTX-M-55}* was found in *S. Agona*, *S. Kentucky*, *S. Typhimurium*, and *S. Typhimurium* monophasic variant, as well as minor serotypes such as *S. Kedougou* and *S. Muenster*, whilst some of them were positive for plasmid replicon sequences. Other β-lactamase such as *bla_{CARB-2}*, *bla_{LAP-2}*, and *bla_{DHA-1}* were also identified in *Salmonella* isolates. *bla_{LAP-2}* was flanked by mobile elements (*IS26*, *ISAs17*, and *ISKpn19*) which could cluster and be combined with resistance genes of plasmids [49]. One *S. Albany* isolate was positive for *bla_{CARB-2}* as well as *tet(G)* in this study. This feature seems common in *S. Typhimurium* strains in Mexico, since genomic island 1 harbors a class-1 integron containing multiple gene cassettes (i.e., *aadA2*, *bla_{CARB-2}*, *floR*, *sul1*, *tet(G)*) [50]. DHA-1, belonging to class C β-lactamases, was identified in *S. Montevideo* and *S. Indiana* isolates of clinical and animal origins [51,52]. We found one *S. Stanley* isolate that carried *bla_{DHA-1}* together with other resistance genes including *bla_{TEM-1B}*, *bla_{OXA-10}*, *msr(E)*, and *floR*. Plasmid replicons like IncHI2/IncHI2A, IncN, and IncR were identified in this isolate.

Previous studies reported that resistance genes are consistent with the antibiotic resistance phenotypes of the *S. 1,4,[5],12:i:-* in *aac(3)-IV*, *aac(6')-Iaa*, *bla_{TEM}*, *bla_{CTX-M}*, *sul*, *tet*, and *mcr*, as well as plasmid-mediated quinolone resistance genes like *oqxAB*, *qnrS*, and *qnrB* [53]. In this study, various horizontally acquired quinolone-resistant genes (*qnrS1*, *qnrB6*, *qnrS2*, *qnrB4*, *qnrB19*, *aac(6')-Ib-cr*, and *oqxAB*) were identified in 106 isolates. Over half of them (64/106) conferred resistance to nalidixic acid and/or ciprofloxacin. A total of 19 isolates were resistant to azithromycin. Four azithromycin resistance determinant profiles were identified in 10 isolates, namely *mph(A)* alone ($n = 7$), *mph(A)-mph(E)-msr(E)-erm(B)* ($n = 1$), *mph(A)-mph(E)-msr(E)* ($n = 1$), and *mph(A)-erm(B)* ($n = 1$). Only one *S. Typhimurium* monophasic variant isolate was found to be positive for a horizontally acquired colistin-resistant gene (*mcr*), but three *S. Enteritidis* isolates and one *S. Typhimurium* monophasic variant isolate showed resistance to colistin and polymyxin. Chromosomally encoded polymyxin-resistant traits might account for its polymyxin resistance phenotype [54]. The

inconsistencies between resistance phenotypes and resistance genes require further comprehensive elucidation at the genetic level.

Isolates of *S. Typhimurium* monophasic variant, the most prevalent serotype in this study, tend to develop resistance against commonly prescribed antibiotics more frequently than those of *S. Typhimurium* and other minor serotypes [55]. The prevalence of *tet(A)* and *tet(B)* in ST34 *Salmonella* 4,[5],12:i:- isolates indicates that there were at least two lineages of 4,[5],12:i:- circulating in Jiaxing City. Reports of resistance to third-generation cephalosporins and colistin in *Salmonella* 4,[5],12:i:- worldwide have become a cause for serious concern in human medicine [27,36,56]. Sequence types of *S. Typhimurium* lineages including ST19, ST34, ST36, and ST313 have been characterized. Among them, monophasic variants of *S. Typhimurium* have been detected in ST34 and ST313 [57]. In our study, all strains of *S. Typhimurium* belonged to ST19, in contrast to ST34 for monophasic *S. Typhimurium* isolates. New strains of monophasic *S. Typhimurium* appear to be continuously emerging from different *S. Typhimurium* strains via different genetic events [26]. The phylogeny analysis in this study revealed that 84 *S. Typhimurium* monophasic variant stains, together with 10 *S. Typhimurium* strains, comprised a unique clone with broad antibiotic resistance.

S. Kentucky is the most prevalent *Salmonella* serovar in chicken and associated samples [17]. Notably, the prevalence of *S. Kentucky* ST198 (6/200 human isolates, 3.0%) in this study was much higher than that among *Salmonella* strains isolated from patients, poultry, and meat products in another study conducted in China from 2013 to 2017 (0.18%) [29]. Ciprofloxacin is a third-generation quinolone used to treat *Salmonella* infection in immunocompromised patients [58]. It is worth mentioning that all *S. Kentucky* isolates in this study were resistant to ciprofloxacin. Of note, the plasmid-mediated *qnrS1* gene, which confers reduced susceptibility to ciprofloxacin, was carried by two ST198.2-2 *S. Kentucky* isolates. Point mutations in quinolone-resistance-determining regions (QRDRs) in *gyrA* (p.S83F and p.D87G) and *parC* (p.T57S and p.S80I) resulted in resistance to nalidixic acid and ciprofloxacin for all *S. Kentucky* isolates.

4. Materials and Methods

4.1. Sample Collection

A total of 5019 stool samples from patients with clinical diarrhea (three or more episodes of diarrhea within 24 h, watery or sticky stools, mucus or pus-bloody stools) were collected to isolate *Salmonella* spp. from 1 January 2023, to 31 December 2023. All fecal samples were cultured overnight at 37 °C in local hospitals using Columbia Blood Agar Plates (Chromagar, Paris, France). Suspected colonies were further confirmed by Matrix-assisted Laser Desorption/Ionization Time-of-Flight Mass Spectrometry (MALDI-TOF MS). All *Salmonella* isolates were submitted to the laboratory of Jiaxing Center for Disease Control and Prevention for further validation and serotyping.

Food samples of raw animal meat (48/484), seasoned raw meat (48/484), prepackaged refrigerated cooked meat products (48/484), freshwater products of animals (48/484), chocolate and chocolate products (48/484), cold-prepared ready-to-eat food (192/484), bean products (20/484), and edible fungus (32/484) were collected and forwarded for *Salmonella* spp. testing according to the GB 4789.4-2016 “National Food Safety Standard for Microbiological Examination of Food—*Salmonella* Examination” [59]. Briefly, 25 g food samples were placed in 225 mL of buffered peptone water (BPW) (Hopebio, Qingdao, China) enrichment solution and cultured at 36 °C for 18 h. Then, 1 mL of BPW enrichment solution was pipetted into 10 mL of tetrathionate broth (TTB) (Hopebio, Qingdao, China), and 10 mL of selenite cultures was streaked onto xylose lysine deoxycholate (XLD) agar (Hopebio, Qingdao, China) and chromogenic *Salmonella* agar (Chromagar, Paris, France) and incubated at 36 °C for 24 to 48 h. Suspicious colonies were picked and subjected to biochemical identification using Vitek2 Compact (Biomerieux, Craponne, France).

4.2. Serotyping

Serotyping for the identification of somatic antigen O and flagellar antigens H (phase 1 and 2) was performed by the slide agglutination method according to the White–Kaufmann–Le Minor Scheme. Monophasic *S. Typhimurium* (4,[5]:i:-) was confirmed by PCR assay according to the characterization of the *fliB–fliA* intergenic region and phase 2 (*fliB*) flagellar gene.

4.3. Antimicrobial Susceptibility Testing

Antimicrobial susceptibility testing was performed using the microdilution method as recommended by the Clinical and Laboratory Standards Institute guidelines (CLSI, 2023). The following antimicrobial agents were tested: nalidixic acid (NAL, 2–64 µg/mL), ciprofloxacin (CIP, 0.015–32 µg/mL), ampicillin (AMP, 1–64 µg/mL), ampicillin/sulbactam (AMS, 1/0.5–64/32 µg/mL), cefotaxime (CTX, 0.25–16 µg/mL), ceftazidime (CAZ, 0.5–32 µg/mL), cefoxitin (CFX, 0.5–32 µg/mL), cefazolin (CFZ, 0.25–32 µg/mL), azithromycin (AZM, 2–64 µg/mL), gentamicin (GEN, 1–32 µg/mL), chloramphenicol (CHL, 2–64 µg/mL), imipenem (IMP, 0.25–8 µg/mL), tetracycline (TET, 1–32 µg/mL), colistin (CT, 0.12–8 µg/mL), trimethoprim/sulfamethoxazole (SXT, 0.5/9.5–8/152 µg/mL), polymyxin (POL, 0.12–4 µg/mL), amikacin (AMI, 4–64 µg/mL), meropenem (MEM, 0.12–4 µg/mL), er-tapenem (ETP, 0.25–8 µg/mL), amoxicillin/clavulanic acid (AMC, 2/1–64/32 µg/mL), ceftazidime (CZA, 0.25/4–8/4 µg/mL), cefepime (CPM, 1–32 µg/mL), streptomycin (STR, 4–32 µg/mL), and amoxicillin/clavulanic acid (AMC, 2/1–64/32 µg/mL). Minimum inhibitory concentration (MIC) was interpreted by CLSI breakpoints (CLSI M100, 2023) [60]. ATCC 25922 was used as quality control strain for susceptibility testing.

4.4. Whole-Genome Sequencing and Bioinformatics Analyses

Genomic DNA was extracted using the QIAamp DNA mini kit (Qiagen, Hilden, Germany) following the manufacturer's protocol. Libraries were prepared for Illumina pair-end sequencing using the NEB Next Ultra DNA Library Prep Kit for Illumina (New England Biolabs, Ipswich, MA, USA) and sequenced in a NextSeq 550 sequencer (Illumina platform) (Illumina, San Diego, CA, USA) (150-bp paired-end reads with about >100-fold average coverage). Reads were assembled using SPAdes 3.6.

4.5. Genomic Analysis

Serovars assigned from Kauffmann–White scheme were confirmed by SeqSero2 v1.1.1 [61]. Annotation of mobile elements was carried out using online databases such as ISfinder [62]. Plasmid replicons and antibiotic resistance genes were detected by uploading the assembled data to online databases found in Center for Genomic Epidemiology (<https://www.genomicepidemiology.org/>, accessed on 30 March 2024.) (PlasmidFinder 2.1 and ResFinder 4.1, respectively). Chromosomal mutations mediating AMR in *acrB*, *pmrA*, *pmrB*, *gyrA*, *gyrB*, *parC*, *parE*, and 16S-*rrsD* were detected by BLAST. In silico 7-gene MLST was performed using the Sequence query tool implemented in the PubMLST Salmonella database. Full genomes of 215 isolates were compared based on their nucleotides composition and sequences by using the BioNumerics software version 7.6 (Applied Maths, Sint-Martens-Latem, Belgium). Forward and reverse fastq files were imported, and the quality of the individual reads was analyzed. A total of 203 sequences were subjected to phylogenetic analysis. A similarity matrix was calculated and used to construct a dendrogram based on the unweighted pair group method (UPGM). The visualization and annotation of the phylogenetic tree were carried out using Itol [63].

4.6. Nucleotide Sequence Accession Numbers

The genomes of the 203 *Salmonella* isolates reported in this study have been deposited in the National Center for Biotechnology Information and registered as BioProject numbers PRJNA1109708, PRJNA1109717, PRJNA1109739, PRJNA1109748, PRJNA1109751, PR-

JNA1109762, PRJNA1109925, PRJNA1109927, PRJNA1109930, PRJNA1109934, PRJNA1109983, PRJNA1109997, PRJNA1110000, PRJNA1110008, and PRJNA1110012.

5. Conclusions

In conclusion, we identified 215 *Salmonella* isolates from clinical diarrhea and food samples collected from Jiaxing City, China. *S. Typhimurium* monophasic variant, *S. Typhimurium*, *S. London*, *S. Enteritidis*, and *S. Rissen* were the most prevalent serotypes among these positive isolates. The majority of *Salmonella* isolates were mainly resistant to ampicillin, tetracycline, chloramphenicol, and trimethoprim/sulfamethoxazole. *bla_{TEM-1B}*, *bla_{OXA-10}*, and *bla_{CTX-M-65}* were three major acquired extended-spectrum β-lactamase-encoding genes. A total of 32 types of plasmid replicons were detected, with *IncQ1* being the most abundant, followed by *IncHI2/IncHI2A* and *IncR*. The highest antibiotic resistance rates were identified among *S. Kentucky* isolates in both acquired resistance genes and chromosomal point mutation in the quinolone-resistance-determining regions. Compared with ST19 *S. Typhimurium*, *S. Typhimurium* monophasic variant strains belonged to ST34 and exhibited broad antibiotic resistance. Phylogenetic analysis identified a unique clone of monophasic *S. Typhimurium* obtained from humans and animals, suggesting that they may have the same origin and may have gone through the same genetic evolutionary event. This study provides further insights into *Salmonella* characterization and provides a foundation for further scientific research. The inconsistencies between resistance phenotypes and resistance genes need further investigation.

Supplementary Materials: The following supporting information can be downloaded at: <https://www.mdpi.com/article/10.3390/antibiotics13050443/s1>, Table S1: Characterizations of *Salmonella* isolates in this study; Table S2: MIC values of *Salmonella* isolates in this study; Table S3: Resistant genes carried in all, *S. Typhimurium*, and *S. Typhimurium* monophasic variant isolates.

Author Contributions: Conceptualization, Z.C. and G.Z.; methodology, P.L. and M.J.; software, L.G.; validation, L.Z., Y.S. and H.W.; data curation, H.W.; writing—original draft preparation, P.L.; writing—review and editing, Z.C. and L.Z.; supervision, Y.Y.; funding acquisition, P.L. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by the Medical Science and Technology Program of Zhejiang Province (2024KY1697) and the Science and Technology Bureau of Jiaxing City: No. 2023AY31028 and No.2022AY30002.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: The data can be obtained upon request from the corresponding author.

Conflicts of Interest: The authors declare no conflicts of interest.

References

- Balasubramanian, R.; Im, J.; Lee, J.S. The global burden and epidemiology of invasive non-typhoidal *Salmonella* infections. *Hum. Vaccin. Immunother.* **2019**, *15*, 1421–1426. [[CrossRef](#)]
- Keestra-Gounder, A.M.; Tsolis, R.M.; Bäumler, A.J. Now you see me, now you don't: The interaction of *Salmonella* with innate immune receptors. *Nat. Rev. Microbiol.* **2015**, *13*, 206–216. [[CrossRef](#)] [[PubMed](#)]
- Verma, A.; Anand, A. Addressing the Multifaceted Challenge of *Salmonella*: Comprehensive Analysis of a Recent Outbreak and Future Strategies. *Asia Pac. J. Public Health* **2024**, *36*, 299–300. [[CrossRef](#)] [[PubMed](#)]
- The European Union One Health 2022 Zoonoses Report. *EFSA J. Eur. Food Saf. Auth.* **2023**, *21*, e8442. [[CrossRef](#)]
- Issenhuth-Jeanjean, S.; Roggentin, P.; Mikoleit, M.; Guibourdenche, M.; de Pinna, E.; Nair, S.; Fields, P.I.; Weill, F.X. Supplement 2008–2010 (no. 48) to the White-Kauffmann-Le Minor scheme. *Res. Microbiol.* **2014**, *165*, 526–530. [[CrossRef](#)]
- Rabsch, W.; Tschäpe, H.; Bäumler, A.J. Non-typhoidal salmonellosis: Emerging problems. *Microbes Infect.* **2001**, *3*, 237–247. [[CrossRef](#)]
- Ao, T.T.; Feasey, N.A.; Gordon, M.A.; Keddy, K.H.; Angulo, F.J.; Crump, J.A. Global burden of invasive nontyphoidal *Salmonella* disease, 2010(1). *Emerg. Infect. Dis.* **2015**, *21*, 941–949. [[CrossRef](#)] [[PubMed](#)]
- Gordon, M.A. Invasive nontyphoidal *Salmonella* disease: Epidemiology, pathogenesis and diagnosis. *Curr. Opin. Infect. Dis.* **2011**, *24*, 484–489. [[CrossRef](#)]

9. Harvey, R.R.; Friedman, C.R.; Crim, S.M.; Judd, M.; Barrett, K.A.; Tolar, B.; Folster, J.P.; Griffin, P.M.; Brown, A.C. Epidemiology of *Salmonella enterica* Serotype Dublin Infections among Humans, United States, 1968–2013. *Emerg. Infect. Dis.* **2017**, *23*, 1493–1501. [[CrossRef](#)]
10. Mohammed, M.; Le Hello, S.; Leekitcharoenphon, P.; Hendriksen, R. The invasome of *Salmonella* Dublin as revealed by whole genome sequencing. *BMC Infect. Dis.* **2017**, *17*, 544. [[CrossRef](#)]
11. Nambiar, R.B.; Elbediwi, M.; Ed-Dra, A.; Wu, B.; Yue, M. Epidemiology and antimicrobial resistance of *Salmonella* serovars Typhimurium and 4,[5]12:i- recovered from hospitalized patients in China. *Microbiol. Res.* **2024**, *282*, 127631. [[CrossRef](#)]
12. Zhao, Q.Y.; Zhang, L.; Yang, J.T.; Wei, H.J.; Zhang, Y.H.; Wang, J.Y.; Liu, W.Z.; Jiang, H.X. Diversity of evolution in MDR monophasic *S. Typhimurium* among food animals and food products in Southern China from 2011 to 2018. *Int. J. Food Microbiol.* **2024**, *412*, 110572. [[CrossRef](#)] [[PubMed](#)]
13. Napoleoni, M.; Villa, L. Monophasic Variant of *Salmonella* Typhimurium 4,[5]12:i- (ACSSuGmTmpSxt Type) Outbreak in Central Italy Linked to the Consumption of a Roasted Pork Product (Porchetta). *Microorganisms* **2023**, *11*, 2567. [[CrossRef](#)]
14. Lamichhane, B.; Mawad, A.M.M. Salmonellosis: An Overview of Epidemiology, Pathogenesis, and Innovative Approaches to Mitigate the Antimicrobial Resistant Infections. *Antibiotics* **2024**, *13*, 76. [[CrossRef](#)] [[PubMed](#)]
15. Pitti, M.; Garcia-Vozmediano, A. Monitoring of Antimicrobial Resistance of *Salmonella* Serotypes Isolated from Humans in Northwest Italy, 2012–2021. *Pathogens* **2023**, *12*, 89. [[CrossRef](#)]
16. Medalla, F.; Gu, W.; Mahon, B.E.; Judd, M.; Folster, J.; Griffin, P.M.; Hoekstra, R.M. Estimated Incidence of Antimicrobial Drug-Resistant Nontyphoidal *Salmonella* Infections, United States, 2004–2012. *Emerg. Infect. Dis.* **2016**, *23*, 29–37. [[CrossRef](#)]
17. Wang, Z.; Jiang, Y.; Xu, H.; Jiao, X.; Wang, J.; Li, Q. Poultry production as the main reservoir of ciprofloxacin- and tigecycline-resistant extended-spectrum β-lactamase (ESBL)-producing *Salmonella enterica* serovar Kentucky ST198.2-2 causing human infections in China. *Appl. Environ. Environ. Microbiol.* **2023**, *89*, e0094423. [[CrossRef](#)]
18. Drieux, L.; Brossier, F.; Sougakoff, W.; Jarlier, V. Phenotypic detection of extended-spectrum beta-lactamase production in Enterobacteriaceae: Review and bench guide. *Clin. Microbiol. Infect.* **2008**, *14* (Suppl. S1), 90–103. [[CrossRef](#)] [[PubMed](#)]
19. Mohammed, M.; Casjens, S.R.; Millard, A.D.; Harrison, C.; Gannon, L.; Chattaway, M.A. Genomic analysis of Anderson typing phages of *Salmonella* Typhimurium: Towards understanding the basis of bacteria-phage interaction. *Sci. Rep.* **2023**, *13*, 10484. [[CrossRef](#)]
20. Arrieta-Gisasola, A.; Atxaerandio-Landa, A.; Garrido, V. Genotyping Study of *Salmonella* 4,[5]12:i- Monophasic Variant of Serovar Typhimurium and Characterization of the Second-Phase Flagellar Deletion by Whole Genome Sequencing. *Microorganisms* **2020**, *8*, 2049. [[CrossRef](#)]
21. Machado, J.; Bernardo, F. Prevalence of *Salmonella* in chicken carcasses in Portugal. *J. Appl. Bacteriol.* **1990**, *69*, 477–480. [[CrossRef](#)] [[PubMed](#)]
22. Elnekave, E.; Hong, S.; Mather, A.E.; Boxrud, D.; Taylor, A.J.; Lappi, V.; Johnson, T.J.; Vannucci, F.; Davies, P.; Hedberg, C.; et al. *Salmonella enterica* Serotype 4,[5]12:i- in Swine in the United States Midwest: An Emerging Multidrug-Resistant Clade. *Clin. Infect. Dis.* **2018**, *66*, 877–885. [[CrossRef](#)] [[PubMed](#)]
23. Mather, A.E.; Phuong, T.L.T.; Gao, Y.; Clare, S.; Mukhopadhyay, S.; Goulding, D.A.; Hoang, N.T.D.; Tuyen, H.T.; Lan, N.P.H.; Thompson, C.N.; et al. New Variant of Multidrug-Resistant *Salmonella enterica* Serovar Typhimurium Associated with Invasive Disease in Immunocompromised Patients in Vietnam. *mBio* **2018**, *9*, e01056-18. [[CrossRef](#)] [[PubMed](#)]
24. Hopkins, K.L.; Kirchner, M.; Guerra, B.; Granier, S.A.; Lucarelli, C.; Porrero, M.C.; Jakubczak, A.; Threlfall, E.J.; Mevius, D.J. Multiresistant *Salmonella enterica* serovar 4,[5]12:i- in Europe: A new pandemic strain? *Euro. Surveill.* **2010**, *15*, 19580. [[CrossRef](#)]
25. Mulvey, M.R.; Finley, R.; Allen, V.; Ang, L.; Bekal, S.; El Bailey, S.; Haldane, D.; Hoang, L.; Horsman, G.; Louie, M.; et al. Emergence of multidrug-resistant *Salmonella enterica* serotype 4,[5]12:i- involving human cases in Canada: Results from the Canadian Integrated Program on Antimicrobial Resistance Surveillance (CIPARS), 2003–2010. *J. Antimicrob. Chemother.* **2013**, *68*, 1982–1986. [[CrossRef](#)] [[PubMed](#)]
26. Ingle, D.J.; Ambrose, R.L.; Baines, S.L.; Duchene, S.; Gonçalves da Silva, A.; Lee, D.Y.J.; Jones, M.; Valcanis, M.; Taiaroa, G.; Ballard, S.A. Evolutionary dynamics of multidrug resistant *Salmonella enterica* serovar 4,[5]12:i- in Australia. *Nat. Commun.* **2021**, *12*, 4786. [[CrossRef](#)] [[PubMed](#)]
27. Sun, R.Y.; Ke, B.X.; Fang, L.X.; Guo, W.Y.; Li, X.P.; Yu, Y.; Zheng, S.L.; Jiang, Y.W.; He, D.M.; Sun, J.; et al. Global clonal spread of mcr-3-carrying MDR ST34 *Salmonella enterica* serotype Typhimurium and monophasic 1,4,[5]12:i- variants from clinical isolates. *J. Antimicrob. Chemother.* **2020**, *75*, 1756–1765. [[CrossRef](#)] [[PubMed](#)]
28. Vázquez, X.; Fernández, J.; Bances, M.; Lumbreiras, P.; Alkorta, M.; Hernández, S.; Prieto, E.; de la Iglesia, P.; de Toro, M.; Rodicio, M.R.; et al. Genomic Analysis of Ciprofloxacin-Resistant *Salmonella enterica* Serovar Kentucky ST198 From Spanish Hospitals. *Front. Microbiol.* **2021**, *12*, 720449. [[CrossRef](#)]
29. Chen, H.; Song, J.; Zeng, X.; Chen, D.; Chen, R.; Qiu, C.; Zhou, K. National Prevalence of *Salmonella enterica* Serotype Kentucky ST198 with High-Level Resistance to Ciprofloxacin and Extended-Spectrum Cephalosporins in China, 2013 to 2017. *mSystems* **2021**, *6*, e00935-20. [[CrossRef](#)]
30. Fang, L.; Lin, G.; Li, Y.; Lin, Q.; Lou, H.; Lin, M.; Hu, Y.; Xie, A.; Zhang, Q.; Zhou, J.; et al. Genomic characterization of *Salmonella enterica* serovar Kentucky and London recovered from food and human salmonellosis in Zhejiang Province, China (2016–2021). *Front. Microbiol.* **2022**, *13*, 961739. [[CrossRef](#)]

31. Le Hello, S.; Weill, F.X.; Guibert, V.; Praud, K.; Cloeckaert, A.; Doublet, B. Early strains of multidrug-resistant *Salmonella enterica* serovar Kentucky sequence type 198 from Southeast Asia harbor *Salmonella* genomic island 1-J variants with a novel insertion sequence. *Antimicrob. Agents Chemother.* **2012**, *56*, 5096–5102. [CrossRef] [PubMed]
32. Hawkey, J.; Le Hello, S.; Doublet, B.; Granier, S.A.; Hendriksen, R.S.; Fricke, W.F.; Ceyssens, P.J.; Gomart, C.; Billman-Jacobe, H.; Holt, K.E.; et al. Global phylogenomics of multidrug-resistant *Salmonella enterica* serotype Kentucky ST198. *Microb. Genom.* **2019**, *5*, e000269. [CrossRef]
33. Wang, J.; Mei, C.-Y.; Wu, H.; Wang, Y.; Wang, Z.-Y.; Ma, Q.-C.; Shen, P.-C.; Zhou, Y.-Y.; Jiao, X. First detection of CTX-M-14-producing multidrug-resistant *Salmonella enterica* serotype Kentucky ST198 epidemic clone from a retail vegetable, China. *J. Glob. Antimicrob. Resist.* **2021**, *26*, 252–254. [CrossRef] [PubMed]
34. Zhang, J.; Jin, H.; Hu, J.; Yuan, Z.; Shi, W.; Ran, L.; Zhao, S.; Yang, X.; Meng, J.; Xu, X. Serovars and antimicrobial resistance of non-typhoidal *Salmonella* from human patients in Shanghai, China, 2006–2010. *Epidemiol. Infect.* **2014**, *142*, 826–832. [CrossRef] [PubMed]
35. Kahsay, A.G.; Dejene, T.A. A Systematic review on Prevalence, Serotypes and Antibiotic resistance of *Salmonella* in Ethiopia, 2010–2022. *Infect. Drug Resist.* **2023**, *16*, 6703–6715. [CrossRef] [PubMed]
36. Long, L.; You, L.; Wang, D.; Wang, M.; Wang, J.; Bai, G.; Li, J.; Wei, X. Highly prevalent MDR, frequently carrying virulence genes and antimicrobial resistance genes in *Salmonella enterica* serovar 4,[5],12:i:- isolates from Guizhou Province, China. *PLoS ONE* **2022**, *17*, e0266443. [CrossRef] [PubMed]
37. Zhou, L.; Zhang, T.J.; Zhang, W.; Xie, C.; Yang, Y.; Chen, X.; Wang, Q.; Wang, H.N.; Lei, C.W. Prevalence and genetic diversity of multidrug-resistant *Salmonella Typhimurium* monophasic variant in a swine farm from China. *Front. Microbiol.* **2023**, *14*, 1200088. [CrossRef] [PubMed]
38. Woh, P.Y.; Yeung, M.P.S.; Goggins, W.B., 3rd; Lo, N.; Wong, K.T.; Chow, V.; Chau, K.Y.; Fung, K.; Chen, Z. Genomic Epidemiology of Multidrug-Resistant Nontyphoidal *Salmonella* in Young Children Hospitalized for Gastroenteritis. *Microbiol. Spectr.* **2021**, *9*, e0024821. [CrossRef]
39. Xu, D.; Chen, L.; Lu, Z.; Wu, X. Prevalence and Serotyping of *Salmonella* in Retail Food in Huzhou China. *J. Food Prot.* **2024**, *87*, 100219. [CrossRef]
40. Popa, G.L.; Papa, M.I. *Salmonella* spp. infection—A continuous threat worldwide. *Germs* **2021**, *11*, 88–96. [CrossRef]
41. Lund, S.; Tahir, M.; Vohra, I.I.; Hamdانا, A.H.; Ahmad, S. Outbreak of monophasic *Salmonella Typhimurium* Sequence Type 34 linked to chocolate products. *Ann. Med. Surg.* **2022**, *82*, 104597. [CrossRef]
42. Peruzy, M.F.; Proroga, Y.T.R.; Capuano, F.; Mancusi, A.; Montone, A.M.I.; Cristiano, D.; Balestrieri, A.; Murru, N. Occurrence and distribution of *Salmonella* serovars in carcasses and foods in southern Italy: Eleven-year monitoring (2011–2021). *Front. Microbiol.* **2022**, *13*, 1005035. [CrossRef] [PubMed]
43. Kyule, D.N.; Maingi, J.M. Molecular Characterization and Diversity of Bacteria Isolated from Fish and Fish Products Retailed in Kenyan Markets. *Int. J. Food Sci.* **2022**, *2022*, 2379323. [CrossRef]
44. Samarasakera, U. *Salmonella Typhimurium* outbreak linked to chocolate. *Lancet Infect. Dis.* **2022**, *22*, 947. [CrossRef]
45. Larkin, L.; Pardos de la Gandara, M.; Hoban, A.; Pulford, C.; Jourdan-Da Silva, N.; de Valk, H.; Browning, L.; Falkenhorst, G.; Simon, S.; Lachmann, R.; et al. Investigation of an international outbreak of multidrug-resistant monophasic *Salmonella Typhimurium* associated with chocolate products, EU/EEA and United Kingdom, February to April 2022. *Euro Surveill.* **2022**, *27*, 2200314. [CrossRef]
46. Bush, K.; Jacoby, G.A. Updated functional classification of beta-lactamases. *Antimicrob. Agents Chemother.* **2010**, *54*, 969–976. [CrossRef]
47. Nadimpalli, M.; Fabre, L.; Yith, V.; Sem, N.; Gouali, M.; Delarocque-Astagneau, E.; Sreng, N.; Le Hello, S. CTX-M-55-type ESBL-producing *Salmonella enterica* are emerging among retail meats in Phnom Penh, Cambodia. *J. Antimicrob. Chemother.* **2019**, *74*, 342–348. [CrossRef] [PubMed]
48. Zhang, C.-Z.; Ding, X.-M.; Lin, X.-L.; Sun, R.-Y.; Lu, Y.-W.; Cai, R.-M.; Webber, M.A.; Ding, H.-Z.; Jiang, H.-X. The Emergence of Chromosomally Located blaCTX-M-55 in *Salmonella* from Foodborne Animals in China. *Front. Microbiol.* **2019**, *10*, 1268. [CrossRef] [PubMed]
49. Shi, Q.; Han, R.; Guo, Y.; Zheng, Y.; Yang, Y.; Yin, D.; Zhang, R.; Hu, F. Emergence of ST15 *Klebsiella pneumoniae* Clinical Isolates Producing Plasmids-Mediated RmtF and OXA-232 in China. *Infect. Drug Resist.* **2020**, *13*, 3125–3129. [CrossRef]
50. Delgado-Suárez, E.J.; Palós-Guitérrez, T.; Ruíz-López, F.A.; Hernández Pérez, C.F.; Ballesteros-Nova, N.E.; Soberanis-Ramos, O.; Méndez-Medina, R.D.; Allard, M.W.; Rubio-Lozano, M.S. Genomic surveillance of antimicrobial resistance shows cattle and poultry are a moderate source of multi-drug resistant non-typhoidal *Salmonella* in Mexico. *PLoS ONE* **2021**, *16*, e0243681. [CrossRef]
51. Kim, J.Y.; Park, Y.J.; Lee, S.O.; Song, W.; Jeong, S.H.; Yoo, Y.A.; Lee, K.Y. Case report: Bacteremia due to *Salmonella enterica* Serotype Montevideo producing plasmid-mediated AmpC beta-lactamase (DHA-1). *Ann. Clin. Lab. Sci.* **2004**, *34*, 214–217.
52. Rayamajhi, N.; Jung, B.Y.; Cha, S.B.; Shin, M.K.; Kim, A.; Kang, M.S.; Lee, K.M.; Yoo, H.S. Antibiotic resistance patterns and detection of blaDHA-1 in *Salmonella* species isolates from chicken farms in South Korea. *Appl. Environ. Microbiol.* **2010**, *76*, 4760–4764. [CrossRef] [PubMed]
53. Qin, X.; Yang, M.; Cai, H.; Liu, Y. Antibiotic Resistance of *Salmonella Typhimurium* Monophasic Variant 1,4,[5],12:i:-in China: A Systematic Review and Meta-Analysis. *Antibiotics* **2022**, *11*, 532. [CrossRef]

54. Landman, D.; Georgescu, C.; Martin, D.A.; Quale, J. Polymyxins revisited. *Clin. Microbiol. Rev.* **2008**, *21*, 449–465. [[CrossRef](#)]
55. Liljebelke, K.A.; Hofacre, C.L.; White, D.G.; Ayers, S.; Lee, M.D.; Maurer, J.J. Diversity of Antimicrobial Resistance Phenotypes in Salmonella Isolated from Commercial Poultry Farms. *Front. Vet. Sci.* **2017**, *4*, 96. [[CrossRef](#)] [[PubMed](#)]
56. Biswas, S.; Li, Y.; Elbediwi, M.; Yue, M. Emergence and Dissemination of mcr-Carrying Clinically Relevant Salmonella Typhimurium Monophasic Clone ST34. *Microorganisms* **2019**, *7*, 298. [[CrossRef](#)] [[PubMed](#)]
57. Pulford, C.V.; Perez-Sepulveda, B.M.; Canals, R. Stepwise evolution of Salmonella Typhimurium ST313 causing bloodstream infection in Africa. *Nat. Microbiol.* **2021**, *6*, 327–338. [[CrossRef](#)] [[PubMed](#)]
58. Jibril, A.H.; Okeke, I.N.; Dalsgaard, A.; Olsen, J.E. Association between antimicrobial usage and resistance in Salmonella from poultry farms in Nigeria. *BMC Vet. Res.* **2021**, *17*, 234. [[CrossRef](#)]
59. GB 4789.4-2016; National Food Safety Standard for Microbiological Examination of Food—Salmonella Examination. China Food and Drug Administration: Beijing, China, 2016.
60. CLSI M100; Performance Standards for Antimicrobial Susceptability Testing. Clinical and Laboratory Standards Institute: Berwyn, PA, USA, 2024.
61. Zhang, S.; den Bakker, H.C.; Li, S.; Chen, J.; Dinsmore, B.A.; Lane, C.; Lauer, A.C.; Fields, P.I.; Deng, X. SeqSero2: Rapid and Improved Salmonella Serotype Determination Using Whole-Genome Sequencing Data. *Appl. Environ. Microbiol.* **2019**, *85*, e01746-19. [[CrossRef](#)]
62. Siguier, P.; Perochon, J.; Lestrade, L.; Mahillon, J.; Chandler, M. ISfinder: The reference centre for bacterial insertion sequences. *Nucleic Acids Res.* **2006**, *34*, D32–D36. [[CrossRef](#)]
63. Letunic, I.; Bork, P. Interactive Tree of Life (iTOL) v5: An online tool for phylogenetic tree display and annotation. *Nucleic Acids Res.* **2021**, *49*, W293–W296. [[CrossRef](#)] [[PubMed](#)]

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.